EUVIMEDEUVIMED entdecken
Vergleichsstudie

Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease

Ross M Maltz iD, Jeremy Adler, ImproveCareNow Pediatric IBD Learning Health System

Journal of Pediatric Gastroenterology and Nutrition · 31.07.2026

DOI: 10.1002/jpn3.70508 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 31.07.2026. Verfasst von Ross M Maltz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Infliximab, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit nennt 31 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate whether children with inflammatory bowel disease (IBD) who initiate infliximab originator versus biosimilar experience similar clinical outcomes at 12 months.

Methods

We conducted a retrospective cohort study evaluating prospectively collected data from the ImproveCareNow (ICN) Network registry. Children

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsInfliximabInflammatory Bowel DiseasesGastrointestinal AgentsHumansFemaleMaleRetrospective StudiesChildTreatment OutcomeAdolescentPropensity ScoreRegistries

Stichwörter der Autor:innen

Crohn's diseaseImproveCareNowanti‐TNFremicadeulcerative colitis

Substanzen

Biosimilar PharmaceuticalsInfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Division of Pediatric Gastroenterology, Michigan Medicine, Ann Arbor, Michigan, USA.
  • Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Ross M Maltz

Förderung

  • None

Zitieren

APA

Maltz, R. M., Adler, J., & ImproveCareNow Pediatric IBD Learning Health System (2026). Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70508

Vancouver

Maltz RM, Adler J, ImproveCareNow Pediatric IBD Learning Health System. Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70508

BibTeX
@article{Maltz2026,
  author = {Maltz, Ross M and Adler, Jeremy and ImproveCareNow Pediatric IBD Learning Health System, ImproveCareNow Pediatric IBD Learning Health System},
  title = {Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70508}
}
Kostenlos starten →